AstraZeneca (AZN) has agreed to acquire EsoBiotec for a total consideration of up to $1 billion, EsoBiotec said Monday.
The consideration consists of an initial payment of $425 million, and up to $575 million in contingency payments.
The deal includes EsoBiotec's Engineered NanoBody Lentiviral delivery platform which has potential application in cancer therapy, the biotechnology company said.
Closing of the deal is expected to occur in Q2, subject to customary closing conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.